Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2016 Sep 28

PMID 27671110

Citations 25

Authors

Gunnveig Grodeland

Agnete Brunsvik Fredriksen

Geir Age Loset

Elisabeth Vikse

Lars Fugger

Bjarne Bogen

Affiliations

Soon will be listed here.

Abstract

It has been difficult to translate promising results from DNA vaccination in mice to larger animals and humans. Previously, DNA vaccines encoding proteins that target Ag to MHC class II (MHC-II) molecules on APCs have been shown to induce rapid, enhanced, and long-lasting Ag-specific Ab titers in mice. In this study, we describe two novel DNA vaccines that as proteins target HLA class II (HLA-II) molecules. These vaccine proteins cross-react with MHC-II molecules in several species of larger mammals. When tested in ferrets and pigs, a single DNA delivery with low doses of the HLA-II-targeted vaccines resulted in rapid and increased Ab responses. Importantly, painless intradermal jet delivery of DNA was as effective as delivery by needle injection followed by electroporation. As an indication that the vaccines could also be useful for human application, HLA-II-targeted vaccine proteins were found to increase human CD4 T cell responses by a factor of ×10 in vitro. Thus, targeting of Ag to MHC-II molecules may represent an attractive strategy for increasing efficacy of DNA vaccines in larger animals and humans.

Citing Articles

Multidrug resistant : A study on its pathogenesis and therapeutics.

Mukhopadhyay H, Bairagi A, Mukherjee A, Prasad A, Roy A, Nayak A Curr Res Microb Sci. 2025; 8():100331.

PMID: 39802320 PMC: 11718326. DOI: 10.1016/j.crmicr.2024.100331.

DNA and protein-generated chimeric molecules for delivery of influenza viral epitopes in mouse and humanized NSG transfer models.

Mihaylova N, Manoylov I, Nikolova M, Prechl J, Tchorbanov A Hum Vaccin Immunother. 2024; 20(1):2292381.

PMID: 38193304 PMC: 10793685. DOI: 10.1080/21645515.2023.2292381.

A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses.

Kuczkowska K, Bjerkan L, Stubsrud E, Husbyn H, Chellappa S, Hauge A Sci Rep. 2023; 13(1):18902.

PMID: 37919366 PMC: 10622562. DOI: 10.1038/s41598-023-46223-8.

Multiple Vaccines and Strategies for Pandemic Preparedness of Avian Influenza Virus.

Xu H, Zhu S, Govinden R, Chenia H Viruses. 2023; 15(8).

PMID: 37632036 PMC: 10459121. DOI: 10.3390/v15081694.

Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine.

Melgoza-Gonzalez E, Bustamante-Cordova L, Hernandez J Front Immunol. 2023; 14:1080238.

PMID: 36969203 PMC: 10038197. DOI: 10.3389/fimmu.2023.1080238.

References

Koff W, Burton D, Johnson P, Walker B, King C, Nabel G . Accelerating next-generation vaccine development for global disease prevention. Science. 2013; 340(6136):1232910. PMC: 4026248. DOI: 10.1126/science.1232910. View

Staudt L, GERHARD W . Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice. J Exp Med. 1983; 157(2):687-704. PMC: 2186921. DOI: 10.1084/jem.157.2.687. View

Lampson L, Levy R . Two populations of Ia-like molecules on a human B cell line. J Immunol. 1980; 125(1):293-9. View

Holte H, Blomhoff H, Beiske K, Funderud S, Torjesen P, Gaudernack G . Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens. Eur J Immunol. 1989; 19(7):1221-5. DOI: 10.1002/eji.1830190711. View

Biragyn A, Tani K, Grimm M, Weeks S, Kwak L . Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol. 1999; 17(3):253-8. DOI: 10.1038/6995. View

Baier G, Baier-Bitterlich G, Looney D, Altman A . Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro. J Virol. 1995; 69(4):2357-65. PMC: 188908. DOI: 10.1128/JVI.69.4.2357-2365.1995. View

Silver J, Ferrone S . Structural polymorphism of human DR antigens. Nature. 1979; 279(5712):436-7. DOI: 10.1038/279436a0. View

Baker N, Sept D, Joseph S, Holst M, McCammon J . Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A. 2001; 98(18):10037-41. PMC: 56910. DOI: 10.1073/pnas.181342398. View

Tunheim G, Thompson K, Fredriksen A, Espevik T, Schjetne K, Bogen B . Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates. Vaccine. 2007; 25(24):4723-34. DOI: 10.1016/j.vaccine.2007.04.004. View

10.

Mjaaland S, Fossum S . Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies. Eur J Immunol. 1990; 20(7):1457-61. DOI: 10.1002/eji.1830200708. View

11.

Schjetne K, Thompson K, Aarvak T, Fleckenstein B, Sollid L, Bogen B . A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol. 2002; 14(12):1423-30. DOI: 10.1093/intimm/dxf110. View

12.

Fredriksen A, Bogen B . Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood. 2007; 110(6):1797-805. DOI: 10.1182/blood-2006-06-032938. View

13.

Solberg O, Mack S, Lancaster A, Single R, Tsai Y, Sanchez-Mazas A . Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol. 2008; 69(7):443-64. PMC: 2632948. DOI: 10.1016/j.humimm.2008.05.001. View

14.

Bergman P, Camps-Palau M, McKnight J, Leibman N, Craft D, Leung C . Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2005; 24(21):4582-5. DOI: 10.1016/j.vaccine.2005.08.027. View

15.

Lambert P, Liu M, Siegrist C . Can successful vaccines teach us how to induce efficient protective immune responses?. Nat Med. 2005; 11(4 Suppl):S54-62. DOI: 10.1038/nm1216. View

16.

Kawamura H, Berzofsky J . Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J Immunol. 1986; 136(1):58-65. View

17.

Schjetne K, Thompson K, Nilsen N, Flo T, Fleckenstein B, Iversen J . Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol. 2003; 171(1):32-6. DOI: 10.4049/jimmunol.171.1.32. View

18.

Lovas T, Bruusgaard J, Oynebraten I, Gundersen K, Bogen B . DNA vaccines: MHC II-targeted vaccine protein produced by transfected muscle fibres induces a local inflammatory cell infiltrate in mice. PLoS One. 2014; 9(10):e108069. PMC: 4191975. DOI: 10.1371/journal.pone.0108069. View

19.

Robinson J, Halliwell J, Hayhurst J, Flicek P, Parham P, Marsh S . The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 2014; 43(Database issue):D423-31. PMC: 4383959. DOI: 10.1093/nar/gku1161. View

20.

Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig M, Steinman R . Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002; 196(12):1627-38. PMC: 2196060. DOI: 10.1084/jem.20021598. View